Last reviewed 2026-05-25 · How we verify

YZJ-1139 simulated tablets

Shanghai Haiyan Pharmaceutical Technology Co., Ltd. · Phase 1 active Small molecule ✓ Verified May 2026

YZJ-1139 simulated tablets is a Small molecule drug developed by Shanghai Haiyan Pharmaceutical Technology Co., Ltd.. It is currently in Phase 1 development.

YZJ-1139 simulated tablets were used in a clinical study to evaluate their interaction with Escitalopram oxalate tablets. The study focused on conditions related to the Central Nervous System, specifically Insomnia.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	YZJ-1139 simulated tablets
Sponsor	Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Clinical Study to Evaluate the Drug Interaction Between YZJ-1139 Tablets and Escitalopram Oxalate Tablets (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

YZJ-1139 simulated tablets CI brief — competitive landscape report
YZJ-1139 simulated tablets updates RSS · CI watch RSS
Shanghai Haiyan Pharmaceutical Technology Co., Ltd. portfolio CI

Frequently asked questions about YZJ-1139 simulated tablets

What is YZJ-1139 simulated tablets?

YZJ-1139 simulated tablets is a Small molecule drug developed by Shanghai Haiyan Pharmaceutical Technology Co., Ltd..

Who makes YZJ-1139 simulated tablets?

YZJ-1139 simulated tablets is developed by Shanghai Haiyan Pharmaceutical Technology Co., Ltd. (see full Shanghai Haiyan Pharmaceutical Technology Co., Ltd. pipeline at /company/shanghai-haiyan-pharmaceutical-technology-co-ltd).

What development phase is YZJ-1139 simulated tablets in?

YZJ-1139 simulated tablets is in Phase 1.

Manufacturer: Shanghai Haiyan Pharmaceutical Technology Co., Ltd. — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing